Ultrasensitive, cost-effective ctDNA-based minimal residual disease (MRD) blood test that monitors cancer recurrence and treatment response using rare mutant allele-enrichment technology. Designed for clinicians and patients, providing accessible, high-performance cancer monitoring beyond elite health systems.